Riverside - Coastal Health Research

Coastal Health

Intervertebral disc disease

BRTX 100

BioRestorative Therapies

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Coastal Health | Riverside - Coastal Health Research

Site insights

Work at this site?

Active trials

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Trial sponsors